Search research articles
Contact Us
Filters
Showing results (91-100 of 232) with videos related to
Page
of 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2017
Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working Group
Lia Gore, S Percy Ivy, Frank M Balis, et al.
Cancer
|
February 27, 2016
Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program
Alexander Drilon, Anne A Eaton, Katja Schindler, et al.
Frontiers in Oncology
|
May 25, 2026
A case report of acute carcinoid heart failure during lutetium-177 dotatate-triapine treatment for well-differentiated neuroendocrine tumors
Aman Chauhan, Elise C Kohn, S Percy Ivy, et al.
The Oncologist
|
August 5, 2010
A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium
Sara K Taylor, Stephen Chia, Susan Dent, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2007
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors
Julie L Eiseman, Jianxia Guo, Ramesh K Ramanathan, et al.
Nature Reviews. Clinical Oncology
|
April 1, 2009
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer
Elizabeth R Gerstner, Dan G Duda, Emmanuelle di Tomaso, et al.
Investigational New Drugs
|
August 4, 2009
Phase II study of sunitinib malate in head and neck squamous cell carcinoma
Nicholas W Choong, Mark Kozloff, David Taber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 5, 2010
Toxicity of sunitinib plus bevacizumab in renal cell carcinoma
Brian I Rini, Jorge A Garcia, Matthew M Cooney, et al.
Clinical Prostate Cancer
|
October 4, 2005
A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer
Elisabeth I Heath, Melvin Gaskins, Henry C Pitot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 2, 2015
Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities
Anne Eaton, Alexia Iasonos, Mrinal M Gounder, et al.
Page
of 24
Search research articles
Search
Showing results (91-100 of 232) with videos related to
Sort By:
Page
of 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2017
Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working Group
Lia Gore, S Percy Ivy, Frank M Balis, et al.
Cancer
|
February 27, 2016
Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program
Alexander Drilon, Anne A Eaton, Katja Schindler, et al.
Frontiers in Oncology
|
May 25, 2026
A case report of acute carcinoid heart failure during lutetium-177 dotatate-triapine treatment for well-differentiated neuroendocrine tumors
Aman Chauhan, Elise C Kohn, S Percy Ivy, et al.
The Oncologist
|
August 5, 2010
A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium
Sara K Taylor, Stephen Chia, Susan Dent, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2007
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors
Julie L Eiseman, Jianxia Guo, Ramesh K Ramanathan, et al.
Nature Reviews. Clinical Oncology
|
April 1, 2009
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer
Elizabeth R Gerstner, Dan G Duda, Emmanuelle di Tomaso, et al.
Investigational New Drugs
|
August 4, 2009
Phase II study of sunitinib malate in head and neck squamous cell carcinoma
Nicholas W Choong, Mark Kozloff, David Taber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 5, 2010
Toxicity of sunitinib plus bevacizumab in renal cell carcinoma
Brian I Rini, Jorge A Garcia, Matthew M Cooney, et al.
Clinical Prostate Cancer
|
October 4, 2005
A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer
Elisabeth I Heath, Melvin Gaskins, Henry C Pitot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 2, 2015
Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities
Anne Eaton, Alexia Iasonos, Mrinal M Gounder, et al.
Page
of 24